Author Contributions: SK, ID and PD contributed to the design and execution of clinical aspects of the study. HWC contributed to aspects of the design and execution of clinical aspects of the study and with ZMK and JM also contributed to the design and execution of scientific aspects of the study. SK, ID, PD, ZMK, JM and HWC also contributed to data analysis and interpretation, drafting of the manuscript and approval of the final submitted draft. EPMG conceived, designed and executed scientific aspects of the study, undertook data analysis and interpretation. EPMG also wrote and co-ordinated drafting and submission of the manuscript. Our data demonstrate that oligomeric heterogeneity underlies functional diversity amongst SP-D in health and disease and that dynamic regulation of oligomerisation is an important feature of SP-D biology.
INTRODUCTION:
Surfactant protein-D (SP-D) is a soluble multimeric collagenous C-type lectin. Although initially and most widely described as a lung specific protein, SP-D is also expressed at a number of other mucosal sites [1] . In common with other collectins including mannose binding lectin (MBL) and surfactant protein-A (SP-A), SP-D recognises carbohydrate structures on a wide range of pathogens -including viruses, bacteria and fungal species -in a calcium dependent fashion [2] . The consequences of such recognition vary among the collectins and in the case of SP-D, pathogen agglutination, inhibition of replication and enhanced phagocytosis are primary outcomes. Clearly important, but less well understood, is the ability of SP-D to regulate inflammatory activity. This aspect of SP-D biology is most apparent in the knockout mouse which develops a spontaneous and progressive emphysematous inflammatory lung disease [3] .
SP-D expression has been examined in a number of lung diseases, including cystic fibrosis (CF).
Exacerbations characterised by protracted and ineffective neutrophil dominated inflammatory responses to pulmonary infection are a primary cause of progressive lung damage in CF and for this reason there has been much interest in the pulmonary innate immune system in this population. Although a number of studies have been undertaken, a clear consensus on the status of SP-D in CF has not emerged. Earlier studies demonstrated a near absence of SP-D in CF lung secretions [4] , but more recently µg/ml quantities have been detected in CF bronchoalveolar lavage fluid (BALF) [5] . Furthermore, reports of a complete absence [5] , or significant reduction [4, 6] of SP-D expression in CF patients with infection contrast with others demonstrating relatively abundant immunoreactive SP-D in patients infected with Pseudomonas aeruginosa [7] . Whilst the amount of detectable SP-D in CF BALF correlates negatively with markers of neutrophil activity and SP-D is susceptible to neutrophil mediated inactivation in vitro [5] [6] [7] [8] [9] [10] , the functional status of endogenous SP-D in CF lung secretions has not been systematically addressed. This is important as physiological concentrations of calcium are
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
3 known to protect SP-D from neutrophil mediated protease inactivation [6, [9] [10] [11] and in some studies little or none of the SP-D found in CF exhibits features of proteolytic degradation [7, 12] .
For this reason we wished to examine whether the widely reported inactivation of SP-D by neutrophils in vitro is reflected in the functional status of this molecule in CF lung secretions.
Here we examine the expression of SP-D in airway secretions from two independent CF cohorts and control patients. We also report the first systematic assessment of the SP-D lectin activity in CF using a novel zymosan binding assay.
MATERIALS AND METHODS:

Patient recruitment and sample processing:
Samples were included from two independently collected cohorts of CF patients and a cohort of control patients (see Table 1 ) as follows:
Cohort A (25 samples) was recruited from the Children's CF unit at the University Hospital of
Wales as previously described [13] . Lavage was collected by flexible bronchoscopy in 10/25 cases with the remainder collected by non-bronchoscopic lavage. In all cases lavage was conducted for diagnostic reasons by instillation of 1ml/kg normal saline (up to a maximum of 20ml) which was immediately suctioned back. A portion of this lavage, representing the bronchial airway, was available for this study. Processing and storage of lavage fluid at -80°C occurred within 45 minutes of collection as previously described [13] . Briefly, lavage fluid was centrifuged at 500g/5 min at 4°C, cell free lavage was aliquoted at 25µl and stored at -80°C for later analysis. Among CF cohort A, clinically significant microbes were cultured from 10 samples (Pseudomonas aeruginosa (n=5), Burkholderia cepacia (n=1), Stenotrophomonas maltophilia (n=2; of which n=1 coincident with P. aerugionosa), Aspergillus fumigatus (n=1),
Moraxella catarrhalis (n=1), Haemophillus influenzae (n=2; of which n=1 coincident with M. Control lavage was collected by non-bronchoscopic lavage from nine non-CF subjects who were undergoing tonsillectomy and/or adenoidectomy at the University Hospital of Wales. These patients were well at the time of surgery and were not in receipt of medication for respiratory symptoms as previously reported [13] . Samples were processed and stored as described for CF cohort A. For this cohort and CF cohort A, ethical approval was obtained from the South East
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Wales Local Research Ethics Committee and written informed consent was obtained.
Cohort B (19 samples) was recruited as previously described [11] from Southampton General
Hospital from children undergoing fiberoptic bronchoscopy for diagnostic reasons. For cohort B, 3 x 10ml portions of normal saline were instilled and aspirated in children younger than 3 years of age. This was increased to 3 x 20ml portions in children > 3 years of age. This sampling represents bronchoalveolar lavage (BAL). The study was approved by the Southampton and Wessex Local Research Ethics Committees and written informed consent was obtained from the parents. BAL from cohort B was initially filtered through a 100µm nylon cell strainer (BD Biosciences) prior to centrifugation at 500g/10 minutes at 4°C. Aspirated cell free BALF was immediately stored at -80°C. For this study, 1ml aliquots from cohort B were available.
Consequently, one freeze/thaw cycle was undertaken on these samples to prepare 25µl aliquots subsequently used throughout the study. A single freeze thaw step was found to have no discernible impact on SP-D binding activity and recovery when determined for three lavage fluid samples (data not shown). Limited clinical data and no microbiology data were available for cohort B and this cohort was primarily used to independently replicate observations made with the main cohort A. Owing to some differences in collection and processing methodologies, no direct comparison was made between cohort B and either cohort A or the control cohort.
5
Immediately prior to analysis, samples from both cohorts were thawed on ice and subjected to micro-centrifugation at 10,000g for 1 minute. Not all samples from the original studies were available for analysis here.
Reagents:
Unless otherwise stated, all reagents were from Fisher Scientific (Loughborough, UK). Affinity purified goat anti-human SP-D raised against recombinant human SP-D was from R&D systems (Abingdon, UK). Minimally cross reactive HRPO-conjugated donkey anti-goat IgG was from Jackson ImmunoResearch (Suffolk, UK). Native SP-D was purified from pulmonary alveolar proteinosis bulk lavage as previously described [14] , and stored at -80°C in the presence of 1mM EDTA.
ELISA:
SP-D was quantified in lavage fluid using a two monoclonal antibody sandwich ELISA from Hycult Biotech (Uden, Netherlands) according to the manufacturer's instructions (measurable range: 6.3-400ng/ml). Lavage samples were diluted between 1:2 and 1:100 and measured in duplicate. Values for CXCL8 have previously been reported in cohort A [13] but not in the context of SP-D expression; this novel analysis is reported here.
Elastase activity assays:
Values for elastase activity in cohorts A and B have been previously reported [11, 13] but not in the context of SP-D expression; this novel analysis is reported here.
Zymosan and maltose-agarose binding assays:
10µl of a Zymosan-A suspension (1% w/v in 154mM NaCl) was added to a 0.5ml microcentrifuge tube and washed twice with 10 volumes of TBS-Ca (20mM Tris-HCl, 154mM
NaCl, 20mM CaCl2; pH 7.6) with microcentrifugation at 10,000g (13,000rpm at r=5.3cm) for 1 minute between washes. The pellet was resuspended with 10µl of TBS-Ca and 10µl of either For all assay formats, samples were incubated for 30 minutes at 37°C with occasional gentle mixing to maintain zymosan in suspension over the course of the assay. Post assay, samples were microcentrifuged at 10,000g for 1 minute and the supernatant was carefully aspirated to a fresh tube, avoiding disturbance of the zymosan pellet. Following aspiration of the supernatant, the zymosan pellet was washed once with 100µl TBS-Ca as described above and the washed pellet was resuspended in 20µl TBS with 20mM EDTA. Where samples were subsequently subjected to SDS-PAGE both pellet and supernatant fractions were immediately treated with SDS sample buffer with β-mercaptoethanol as a reducing agent and boiled at 100°C for 2 minutes prior to electrophoretic separation. For native-PAGE, samples were treated with cold sample buffer without SDS but supplemented with 0.002% Coomassie Blue G250 (Sigma, UK).
Samples were not boiled but immediately separated as described below. The reproducibility of the zymosan binding assay was confirmed by assaying at least seven lavage samples from this and a previous study [15] at different time points up to 10 months apart (data not shown).
Maltose-agarose pull down assays were similar to the zymosan binding assays with the following differences. 10µl of maltose agarose (Sigma, Dorset, UK) was washed three times in 1ml TBS-Ca prior to commencement of the binding assay. Binding steps for both parallel zymosan and maltose-agarose assays were carried out on a flat bed roller to avoid settling of the maltose-agarose during the assay. Assays were carried out in a final volume of 30µl, with only 20µl of the supernatant fraction aspirated for SDS-PAGE to avoid disturbing the agarose pellet;
once washed, the pellet was resuspended in 30µl of TBS-EDTA, 20µl of which was prepared for for SDS-PAGE as described above.
Native-and SDS-PAGE, Western Blot and densitometry:
Native PAGE was performed using NuPage 3-8% Tris-Acetate gels (Life Technologies, UK) and a tris-glycine buffer system where the cathode buffer was supplemented with 0.002% Coomassie Developed blots were scanned and the entire blot area was uniformly adjusted for brightness and contrast. Presented images represent all bands visible in lanes from the original blot.
Densitometry was performed on the blots using ImageJ v1.42 as previously described [13] and Fractions were also assayed for specific SP-D lectin activity in a solid phase mannan binding assay as follows: Maxisorp 96-well plates (Nunc, Denmark) were coated overnight at 37°C with 50µg/ml mannan from S. cerevisiae (Sigma, UK) and blocked with TBS 0.05% Tween 20 (TBST).
Gel chromatography fractions were made 0.05% (v/v) with respect to Tween 20 and 10mM
with respect to either CaCl2 or EDTA. Fractions were applied to mannan coated plates for 90 minutes at room temperature. Plates were washed three times with TBST-10mM calcium (TBST-C) or TBST-10mM EDTA (TBST-E) and goat anti-SP-D (1µg/ml) was applied in TBST-C for 60 minutes at room temperature. Plates were washed and HRPO-conjugated minimally cross reactive donkey anti-goat IgG was applied for 30 minutes at room temperature. Plates were washed, developed with TMB and arrested with H2SO4 before absorbance was measured at 450nm on a SpectraMax 340PC spectrophotometer (Molecular Devices, UK).
Statistics
Unless otherwise indicated, all data presented in the text refer to (median; interquartile range).
Two group comparisons of non-parametric data were undertaken using the Mann-Whitney test.
Spearman's r-values are used to describe correlations. In all cases statistical significance was achieved at p<0.05. Data remained statistically significant after the application of Holm's sequential Bonferroni correction where appropriate [17] . All data were analysed using GraphPad Prism v5.01 (GraphPad Software Inc). and EDTA sensitive (figure 3a) as previously described [15] . When tested in the same assay, lavage fluid from CF cohorts A and B as well as the control cohort contained substantial amounts of SP-D which failed to bind zymosan. Within control and CF lavage, a minor band migrating 3-4kDa and occasionally 6-8kDa (figure 3b&c; closed arrows) higher than the main SP-D monomer (figure 3b&c; asterix) were sometimes identified by Western blot as part of the non-binding SP-D pool. Similar minor forms of higher molecular weight SP-D have previously been described [7, 18] . Occasionally, a minor band migrating below the main SP-D monomer was observed in CF lavage which contained active neutrophil elastase ( figure 3b ; open arrow).
RESULTS:
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This likely corresponds to partially proteolysed SP-D as previously described in CF [6, 7] .
Lavage SP-D interactions with zymosan were also predominantly calcium and maltose dependent ( Figure 3c ). As reported in previous studies [9] [10] [11] , calcium chelation with EDTA in CF lavage sometimes resulted in a loss of detectable SP-D due to proteolysis (data not shown).
Protease inhibition with 1mM PMSF preserved SP-D under these conditions (figure 3c; right hand panel). The pH of airway secretions in normal and pathological conditions has been reported to be slightly acidic. The pH dependence of SP-D zymosan interactions were therefore also tested and were found to be stable when tested between pH 5.6 and 7.6 (figure 3d). 
DISCUSSSION:
We present a comprehensive analysis of SP-D expression and function in lung secretions from paediatric CF patients and controls. To our knowledge, this is the first systematic analysis of SP-D lectin activity in the CF population.
In keeping with previous studies, SP-D expression was reduced in lavage fluid from CF patients with infection or evidence of inflammation compared to non-infected CF patients. Importantly however, SP-D was present in all but a few CF samples representing both bronchial (Cohort A) and bronchoalveolar (Cohort B) airway when tested by specific dual monoclonal antibody ELISA. There has been considerable variability in reported values for BALF SP-D in CF, ranging from a near absence [4, 23] to expression in the µg/ml range [5] . Several factors may explain this variability: In addition to differences in BAL sampling and processing methodology, techniques used to measure SP-D in CF range from semi-quantitative western blot [6, 7] to ELISA, some of which use antibodies reactive with human SP-D but raised against a different species [5, 23] . Also, some previous studies applied specific microbial density thresholds to define infection [5, 6] , whereas we define infection on the basis of reported positive culture in line with other reports [12, [24] [25] [26] . This may explain why we observe immunoreactive SP-D both by Western blot and ELISA even in culture positive CF samples. Also, in some previous studies, the proportion of patients with culture verified infection was higher [4, 7] and the age range of CF patients substantially older [7, 23] than those studied by us. This may be relevant in light of the negative correlation between age, infection and SP-D concentration reported here.
Previous population based studies have described increased circulating SP-D with age [27] . The age related decline in lung rather than circulating SP-D observed here probably reflects advancing lung disease in this population, an interpretation supported by the increased prevalence of infection and active elastase in older patients. In summary, our observation of substantial SP-D expression in CF confirms some reports [5, 7] but not others [4] . However the observed negative association between SP-D, infection and inflammation agrees with the findings of a number of previous studies [4] [5] [6] and suggests that detectable SP-D is subject to dynamic modulation in the face of ongoing inflammatory disease.
The primary objective of this study was to examine the carbohydrate binding activity of SP-D in CF patients. We observed considerable heterogeneity in the capacity of both CF and control lavage SP-D to bind the yeast derived mannan rich particle, zymosan. Such heterogeneity was observed in lavage fluid collected from two distinct cohorts of CF patients. Lavage collected from cohort A was mainly of bronchial origin whilst that from cohort B was reflective of bronchoalveolar lavage according to the lavage procedure used. Nevertheless, inflammatory activity (reflected in free elastase activity) was relatively similar between both cohorts which may reflect the largely bronchial nature of airway disease in CF. Although SP-D inactivation by CF relevant proteases is well described, the functional consequences of this remain unclear as physiological concentrations of calcium render SP-D resistant to proteolysis [6, 9, 11] . As previously reported, SP-D expression was lower in elastase positive CF samples here, however in the majority of cases substrate bound and non-bound SP-D migrated at an identical molecular weight on SDS-PAGE under reducing conditions. The absence of a major population of proteolytically fragmented SP-D in this study is consistent with two previous reports [7, 12] and indicates that limited proteolysis is not responsible for the observed restriction of lectin activity. Minor forms of SP-D migrating 3-8kDa higher than the main monomer were observed in many samples but did not associate with zymosan or maltose-agarose and were exclusively found in the supernatant fraction. These resemble forms of SP-D previously observed in CF BALF [7] and are thought to represent a hyper-glycosylated form of SP-D speculated by Mason et al. to limit oligomerisation to trimeric species [18] . The inability of these forms to bind saccharide ligands in our assays is consistent with the well documented reduction of opsonic and anti-viral activity of low oligomeric forms of SP-D [20] [21] [22] . In light of this, we used both restricted trimeric oligomers [22] . Although the frequency of that polymorphism was not determined here, its distribution among Danish CF patients is not significantly different from the normal population [28] . In addition to these common polymorphisms, post-translational modification by nitric oxide derivatives [29] and elements of the neutrophil respiratory burst observed. We have recently described functionally relevant heterogeneity of SP-D oligomeric form in preterm neonatal BALF using methodology similar to that described here [15] .
Oligomeric diversity has also been observed in SP-D from asthmatic and chronic obstructive pulmonary disease patients [32, 33] [35, 36] and Mycobacterium tuberculosis [37] .
In the case of MBL (another collectin subject to functionally relevant oligomeric variation), amino acid changes influencing multimerisation and carbohydrate binding activity act in combination with promoter polymorphisms to confer a state of functional and quantitative MBL insufficiency [38] associated with earlier and more severe lung pathology in CF [39] . Increased oligomeric complexity in SP-A has also been recently associated with better lung function in CF [40] . The only study published to date in CF identified no association between SP-D Met/Thr genotype and disease progression [28] , however larger studies looking at the full range of factors influencing SP-D structure/function will probably be required to reach a firm conclusion.
In summary, our data show that SP-D is found in substantial quantities in the paediatric CF lung but exists as a functionally and structurally heterogeneous population in both this and the 
